Canakinumab (IL-1β monoclonal antibody)

Current understanding

To be populated as evidence accumulates.

2026-04-13 — A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: cross-connection with canakinumab-anti-il1b-mds-cmml: Both pages cover canakinumab (anti-IL-1β monoclonal antibody); the MDS/CMML page reflects the indication-specific Phase II trial, while the general IL-1β inhibitor page covers the broader mechanism — likely candidates for merging or explicit linking. (novelty: 3)
2026-03-19 — Study of Canakinumab in Patients With Myelofibrosis: Phase 2 open-label multicenter two-stage trial launched evaluating canakinumab 200 mg SC every 3 weeks for 8 cycles in primary and post-ET/PV myelofibrosis (interim n=10, max n=26), with futility stopping for no responses, safety stopping at ≥4 unacceptable toxicities, and final success defined as >3 responses with <7 toxicities. (novelty: 4)